Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Urology Oncology|May 30, 2025
Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical TrialsSatı Coşkun Yazgan, Emre Yekedüz, Mutlay Sayan, et al.
The Oncologist|July 22, 2025
Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapySatı Coşkun Yazgan, Kamil Kayaş, Çağatay Arslan, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer ConsortiumMusa Barış Aykan, Hatice Bölek, Emre Yekedüz, et al.
Clinical Genitourinary Cancer|December 22, 2024
Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) DatabaseHatice Bölek, Elif Sertesen, Omer Faruk Kuzu, et al.
Cancers|July 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) StudyMurat Günaltılı, Hatice Bölek, Esma Kaplan Tüzün, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 7, 2024
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter studySerhat Sekmek, Irfan Karahan, Gokhan Ucar, et al.
JCO Global Oncology|October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 StudyFrancesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Medicina (Kaunas, Lithuania)|May 27, 2026
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World AnalysisMustafa Seyyar, Pervin Can Şancı, Abdullah Sakin, et al.
The Oncologist|May 20, 2026
Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy CombinationsSara Elena Rebuzzi, Aruni Ghose, Sarah Rudman, et al.
Pageof 2